Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA.

Ann Rheum Dis. 2019 Jul 3. pii: annrheumdis-2019-215672. doi: 10.1136/annrheumdis-2019-215672. [Epub ahead of print]

PMID:
31270110
2.

Malignancies In Giant Cell Arteritis: A Population-Based Cohort Study.

Stamatis P, Turesson C, Willim M, Nilsson JÅ, Englund M, Mohammad AJ.

J Rheumatol. 2019 Jun 1. pii: jrheum.190236. doi: 10.3899/jrheum.190236. [Epub ahead of print]

PMID:
31154410
3.

Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome.

Olsson P, Bodewes ILA, Nilsson AM, Turesson C, Jacobsson LTH, Theander E, Versnel MA, Mandl T.

Rheumatol Int. 2019 Sep;39(9):1575-1584. doi: 10.1007/s00296-019-04335-3. Epub 2019 May 28.

PMID:
31139950
4.

Lower extremity function in patients with early rheumatoid arthritis during the first five years, and relation to other disease parameters.

Mellblom Bengtsson M, Hagel S, Jacobsson L, Turesson C.

Scand J Rheumatol. 2019 Apr 29:1-8. doi: 10.1080/03009742.2019.1579859. [Epub ahead of print]

PMID:
31030582
5.

Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis.

Turesson C, Börjesson O, Larsson K, Mohammad AJ, Knight A.

Scand J Rheumatol. 2019 Jul;48(4):259-265. doi: 10.1080/03009742.2019.1571223. Epub 2019 Mar 6.

PMID:
30838907
6.

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.

Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J; ARTIS Study Group .

Rheumatology (Oxford). 2019 Jan 21. doi: 10.1093/rheumatology/key433. [Epub ahead of print]

PMID:
30668875
7.

The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.

Kapetanovic MC, Nilsson P, Turesson C, Englund M, Dalbeth N, Jacobsson L.

Arthritis Res Ther. 2018 Aug 29;20(1):190. doi: 10.1186/s13075-018-1697-6.

8.

Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis.

Bergström U, Jovinge S, Persson J, Jacobsson LTH, Turesson C.

Curr Ther Res Clin Exp. 2018 Jul 23;89:1-6. doi: 10.1016/j.curtheres.2018.07.001. eCollection 2018.

9.

Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study.

Raaschou P, Söderling J, Turesson C, Askling J; ARTIS Study Group.

Ann Intern Med. 2018 Sep 4;169(5):291-299. doi: 10.7326/M17-2812. Epub 2018 Aug 14.

PMID:
30105374
10.

The Role of Hand Therapy in Dupuytren Disease.

Turesson C.

Hand Clin. 2018 Aug;34(3):395-401. doi: 10.1016/j.hcl.2018.03.008. Review.

11.

Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren's syndrome.

Olsson P, Skogstrand K, Nilsson A, Turesson C, Jacobsson LTH, Theander E, Houen G, Mandl T.

Rheumatol Int. 2018 Aug;38(8):1503-1510. doi: 10.1007/s00296-018-4063-8. Epub 2018 May 30.

12.

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.

Rydell E, Forslind K, Nilsson JÅ, Jacobsson LTH, Turesson C.

Arthritis Res Ther. 2018 May 2;20(1):82. doi: 10.1186/s13075-018-1575-2.

13.

Patients' needs during a surgical intervention process for Dupuytren's disease.

Turesson C, Kvist J, Krevers B.

Disabil Rehabil. 2019 Mar;41(6):666-673. doi: 10.1080/09638288.2017.1402095. Epub 2017 Nov 21.

14.

Course of Grip Force Impairment in Patients With Early Rheumatoid Arthritis Over the First Five Years After Diagnosis.

Rydholm M, Book C, Wikström I, Jacobsson L, Turesson C.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):491-498. doi: 10.1002/acr.23318. Epub 2018 Mar 11.

15.

Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors.

Theander L, Nyhäll-Wåhlin BM, Nilsson JÅ, Willim M, Jacobsson LTH, Petersson IF, Turesson C.

J Rheumatol. 2017 Jul;44(7):981-987. doi: 10.3899/jrheum.161103. Epub 2017 May 1.

PMID:
28461642
16.

Cigarette smoking and the risk of primary Sjögren's syndrome: a nested case control study.

Olsson P, Turesson C, Mandl T, Jacobsson L, Theander E.

Arthritis Res Ther. 2017 Mar 7;19(1):50. doi: 10.1186/s13075-017-1255-7.

17.

EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.

Jørgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R, Bliddal H, Geborek P, Kristensen LE.

PLoS One. 2017 Feb 2;12(2):e0169946. doi: 10.1371/journal.pone.0169946. eCollection 2017.

18.

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A.

Clin Rheumatol. 2017 Apr;36(4):773-779. doi: 10.1007/s10067-016-3505-5. Epub 2016 Dec 14.

PMID:
27966068
19.

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study.

Mohammad AJ, Englund M, Turesson C, Tomasson G, Merkel PA.

J Rheumatol. 2017 Jan;44(1):84-90. doi: 10.3899/jrheum.160249. Epub 2016 Nov 1.

PMID:
27803140
20.

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.

Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A.

EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024. Epub 2016 Aug 18.

21.

The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.

Jakobsson K, Jacobsson L, Mohammad AJ, Nilsson JÅ, Warrington K, Matteson EL, Turesson C.

BMC Musculoskelet Disord. 2016 Aug 24;17(1):363. doi: 10.1186/s12891-016-1225-2.

22.

Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors.

Naderi N, Mohammad AJ, Turesson C.

Scand J Rheumatol. 2017 May;46(3):215-221. doi: 10.1080/03009742.2016.1190984. Epub 2016 Jul 6.

PMID:
27385090
23.

Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study.

Saleh M, Turesson C, Englund M, Merkel PA, Mohammad AJ.

J Rheumatol. 2016 Aug;43(8):1559-65. doi: 10.3899/jrheum.151033. Epub 2016 Jun 1.

PMID:
27252424
24.

Multiplex cytokine analyses in patients with rheumatoid arthritis require use of agents blocking heterophilic antibody activity.

Olsson P, Theander E, Bergström U, Jovinge S, Jacobsson L, Turesson C.

Scand J Rheumatol. 2017 Jan;46(1):1-10. doi: 10.3109/03009742.2016.1161070. Epub 2016 May 12.

PMID:
27172254
25.

Comorbidity in rheumatoid arthritis.

Turesson C.

Swiss Med Wkly. 2016 Apr 5;146:w14290. doi: 10.4414/smw.2016.14290. eCollection 2016. Review.

26.

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Cöster L, Forslind K, van Vollenhoven R, Heimbürger M.

RMD Open. 2016 Jan 14;2(1):e000133. doi: 10.1136/rmdopen-2015-000133. eCollection 2016.

27.

Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.

Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A.

Arthritis Rheumatol. 2016 Jun;68(6):1346-52. doi: 10.1002/art.39595.

28.

Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material.

Pikwer M, Orellana C, Källberg H, Pikwer A, Turesson C, Klareskog L, Alfredsson L, Saevarsdottir S, Bengtsson C.

Arthritis Res Ther. 2015 Dec 12;17:358. doi: 10.1186/s13075-015-0869-x.

29.

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries.

Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C.

RMD Open. 2015 Apr 30;1(1):e000040. doi: 10.1136/rmdopen-2014-000040. eCollection 2015.

30.

High serum cholesterol predicts rheumatoid arthritis in women, but not in men: a prospective study.

Turesson C, Bergström U, Pikwer M, Nilsson JÅ, Jacobsson LT.

Arthritis Res Ther. 2015 Oct 12;17:284. doi: 10.1186/s13075-015-0804-1.

31.

A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women.

Turesson C, Bergström U, Pikwer M, Nilsson JÅ, Jacobsson LT.

Rheumatology (Oxford). 2016 Feb;55(2):307-14. doi: 10.1093/rheumatology/kev313. Epub 2015 Sep 8.

PMID:
26350488
32.

Mortality in ankylosing spondylitis: results from a nationwide population-based study.

Exarchou S, Lie E, Lindström U, Askling J, Forsblad-d'Elia H, Turesson C, Kristensen LE, Jacobsson LT.

Ann Rheum Dis. 2016 Aug;75(8):1466-72. doi: 10.1136/annrheumdis-2015-207688. Epub 2015 Sep 2.

PMID:
26338036
33.

The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study.

Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M, Turesson C, Kristensen LE, Jacobsson LT.

Arthritis Res Ther. 2015 May 9;17:118. doi: 10.1186/s13075-015-0627-0.

34.

Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register.

Lindström U, Exarchou S, Sigurdardottir V, Sundström B, Askling J, Eriksson JK, Forsblad-d'Elia H, Turesson C, Kristensen LE, Jacobsson L.

Scand J Rheumatol. 2015;44(5):369-76. doi: 10.3109/03009742.2015.1010572. Epub 2015 Mar 23.

PMID:
25797539
35.

The impact of obesity on the development and progression of rheumatoid arthritis.

Finckh A, Turesson C.

Ann Rheum Dis. 2014 Nov;73(11):1911-3. doi: 10.1136/annrheumdis-2014-205741. No abstract available.

PMID:
25288687
36.

Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.

Bergström U, Grundtman C, Lundberg IE, Jacobsson LT, Nilsson K, Turesson C.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):883-90. Epub 2014 Oct 2.

PMID:
25287961
37.

Body mass index and the risk of giant cell arteritis: results from a prospective study.

Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Liang K, Melander O, Turesson C.

Rheumatology (Oxford). 2015 Mar;54(3):433-40. doi: 10.1093/rheumatology/keu331. Epub 2014 Sep 5.

38.

Nitrosative modifications of the Ca2+ release complex and actin underlie arthritis-induced muscle weakness.

Yamada T, Fedotovskaya O, Cheng AJ, Cornachione AS, Minozzo FC, Aulin C, Fridén C, Turesson C, Andersson DC, Glenmark B, Lundberg IE, Rassier DE, Westerblad H, Lanner JT.

Ann Rheum Dis. 2015 Oct;74(10):1907-14. doi: 10.1136/annrheumdis-2013-205007. Epub 2014 May 22.

39.

Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA-results from a community based study.

Hekmat K, Jacobsson LT, Nilsson JÅ, Lindroth Y, Turesson C.

BMC Musculoskelet Disord. 2014 Feb 20;15:44. doi: 10.1186/1471-2474-15-44.

40.

Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden.

Mohammad AJ, Nilsson JÅ, Jacobsson LT, Merkel PA, Turesson C.

Ann Rheum Dis. 2015 Jun;74(6):993-7. doi: 10.1136/annrheumdis-2013-204652. Epub 2014 Jan 17.

PMID:
24442881
41.

The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men--the MrOS study.

Exarchou S, Redlund-Johnell I, Karlsson M, Mellström D, Ohlsson C, Turesson C, Kristensen LE, Jacobsson L.

BMC Musculoskelet Disord. 2013 Dec 13;14:352. doi: 10.1186/1471-2474-14-352.

42.

COMP-C3b complexes in rheumatoid arthritis with severe extraarticular manifestations.

Happonen KE, Saxne T, Jacobsson L, Sturfelt G, Rönnelid J, Mollnes TE, Heinegård D, Turesson C, Blom AM.

J Rheumatol. 2013 Dec;40(12):2001-5. doi: 10.3899/jrheum.130613. Epub 2013 Nov 1.

PMID:
24187101
43.

Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis.

Turesson C, Mathsson L, Jacobsson LT, Sturfelt G, Rönnelid J.

Ann Rheum Dis. 2013 Dec;72(12):2047-8. doi: 10.1136/annrheumdis-2013-203510. Epub 2013 Jun 5. No abstract available.

PMID:
23740235
44.

Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case-control study.

Pikwer M, Giwercman A, Bergström U, Nilsson JÅ, Jacobsson LT, Turesson C.

Ann Rheum Dis. 2014 Mar;73(3):573-9. doi: 10.1136/annrheumdis-2012-202781. Epub 2013 Apr 3.

PMID:
23553100
45.

Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment.

Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Turesson C.

Scand J Rheumatol. 2013;42(4):331-2. doi: 10.3109/03009742.2013.775330. Epub 2013 Mar 28. No abstract available.

PMID:
23537224
46.

Extra-articular rheumatoid arthritis.

Turesson C.

Curr Opin Rheumatol. 2013 May;25(3):360-6. doi: 10.1097/BOR.0b013e32835f693f. Review.

PMID:
23425964
47.

Smoking, low formal level of education, alcohol consumption, and the risk of rheumatoid arthritis.

Bergström U, Jacobsson LT, Nilsson JÅ, Wirfält E, Turesson C.

Scand J Rheumatol. 2013;42(2):123-30. doi: 10.3109/03009742.2012.723744. Epub 2012 Nov 6.

PMID:
23126587
48.

Early menopause and severity of rheumatoid arthritis in women older than 45 years.

Pikwer M, Nilsson JÅ, Bergström U, Jacobsson LT, Turesson C.

Arthritis Res Ther. 2012 Aug 17;14(4):R190. doi: 10.1186/ar4021.

49.

Malignancy as a comorbidity in rheumatic diseases.

Turesson C, Matteson EL.

Rheumatology (Oxford). 2013 Jan;52(1):5-14. doi: 10.1093/rheumatology/kes189. Epub 2012 Jul 23. Review.

PMID:
22829694
50.

Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors.

Nyhäll-Wåhlin BM, Petersson IF, Jacobsson C, Geborek P, Nilsson JÅ, Nilsson K, Jacobsson LT, Turesson C.

Scand J Rheumatol. 2012;41(6):434-7. doi: 10.3109/03009742.2012.695803. Epub 2012 Jul 20.

PMID:
22813208

Supplemental Content

Loading ...
Support Center